Playback speed
10 seconds
ASCO® 2023 Insights: "A Phase 3 Trial Comparing Fianlimab + Cemiplimab to Pembrolizumab in Pts With Completely Resected High-Risk Melanoma"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Timothy Panella
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Timothy Panella
728 views
June 8, 2023
Login to view comments.
Click here to Login